OTCMKTS:IMUCD ImmunoCellular Therapeutics (IMUCD) Stock Price, News & Analysis $0.09 0.00 (0.00%) As of 10/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About ImmunoCellular Therapeutics Stock (OTCMKTS:IMUCD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IMUCD alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.07▼$0.1052-Week Range$0.16▼$0.51Volume2 shsAverage Volume6,605 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ImmunoCellular Therapeutics (OTCMKTS:IMUCD) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for the treatment of aggressive cancers. The company’s core focus centers on dendritic cell-based vaccines designed to activate a patient’s immune system against tumor-associated antigens. By harnessing the body’s own defense mechanisms, ImmunoCellular aims to improve outcomes for patients with high-unmet-need malignancies, particularly glioblastoma multiforme (GBM). The company’s lead product candidates include ICT-107 and ICT-121, both of which target specific antigens commonly expressed in GBM cells. ICT-107 is a personalized dendritic cell vaccine that has completed Phase 2 clinical trials, demonstrating a tolerable safety profile and preliminary signals of efficacy in newly diagnosed GBM patients. ICT-121 is being evaluated in early-phase studies for recurrent GBM, with the goal of extending survival and delaying disease progression. Beyond brain cancer, ImmunoCellular has also advanced ICT-140, an ovarian cancer vaccine candidate, into preclinical development, underscoring its broader commitment to cell-based oncology therapies. Founded in the mid-2000s and headquartered in Los Angeles, California, ImmunoCellular Therapeutics operates primarily within the United States, collaborating with leading academic medical centers and research institutions. Its research and development efforts leverage partnerships to conduct multi-center clinical trials and to explore combination strategies with emerging immuno-oncology agents. The company’s scientific advisors comprise experts in neuro-oncology, immunology, and cell therapy, guiding its strategic direction and translational research initiatives.AI Generated. May Contain Errors. Read More Receive IMUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoCellular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMUCD Stock News HeadlinesIMUC EOM Pharmaceuticals Holdings, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comRVVTF - Revive Therapeutics Ltd.June 23, 2023 | finance.yahoo.comThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. Right now, all seven are flashing red simultaneously for the first time since 2007. These aren't the signals you'll see on CNBC.October 16 at 2:00 AM | American Alternative (Ad)Blame for Northwest Bio Collapse Lies With CEO, Not With Mythical 'Wolfpack'April 16, 2023 | thestreet.comSee More Headlines IMUCD Stock Analysis - Frequently Asked Questions How have IMUCD shares performed this year? ImmunoCellular Therapeutics' stock was trading at $0.1688 at the beginning of 2025. Since then, IMUCD shares have decreased by 46.7% and is now trading at $0.09. How do I buy shares of ImmunoCellular Therapeutics? Shares of IMUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IMUCD CIKN/A Webwww.imuc.com Phone(818) 264-2300FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.63 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:IMUCD) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoCellular Therapeutics, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoCellular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.